Global Prostate Cancer Testing

Prostate Cancer Testing Comprehensive Study by Type (PSA Tests, CTC Tests, Immunohistochemistry, PCA3 Tests, Others), Application (Hospital Associated Labs, Independent Diagnostic Laboratories, Cancer Research Institutes, Others) Players and Region - Global Market Outlook to 2027

Prostate Cancer Testing Market by XX Submarkets | Forecast Years 2022-2027  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Industry Background:
Prostate Cancer testing is an unusual and unbounded growth of cells in the prostate glands of the male. Prostate Cancer testing market has high growth prospects due to increasing prevalence of disease requiring surgical treatment and introduction of advanced technologies in minimally invasive surgeries. The major companies are adding more proven post-operative recovery and lower post-operative complications in Asia-Pacific countries as these countries are focused on fastest-growing verticals for the healthcare domain. Further, increasing demand for bariatric surgeries and rising applications in insurance coverage expected to drive the market over the forecasted period.

AttributesDetails
Study Period2017-2027
Base Year2021
High Growth MarketAsia Pacific
UnitValue (USD Million)
Key Companies ProfiledGenomic Health (United States), OPKO (United States), Siemens Healthcare (Germany), DiaSorin (Italy), BioMeriux (France), Roche (Switzerland), MDx Health (Belgium), Beckman Coulter (United States), Myriad Genetics (United States) and Ambry Genetics (United States)


This growth is primarily driven by Increase Prevalence of Prostate Cancer and Growing Awareness Regarding the Diseases.

Globally, a noticeable market trend is evident increasing demand in Asia Pacific region The Health Care Services sector in the North America region has been increasing at a sustainable rate and further growth is expected to be witnessed over the forecast period, owing to the robust investments and expansion in production facilities in the region. Major Players, such as Genomic Health (United States), OPKO (United States), Siemens Healthcare (Germany), DiaSorin (Italy), BioMeriux (France), Roche (Switzerland), MDx Health (Belgium), Beckman Coulter (United States), Myriad Genetics (United States) and Ambry Genetics (United States) etc have either set up their manufacturing facilities or are planning to start new provision in the dominated region in the upcoming years.

Key Developments in the Market:
In October 2018, Novartis acquired Endocyte to expand its RLT pipeline in prostate cancer. This acquisition is beneficial for treatments of oncology with imaging agents designed to assist in therapy selection.
In July 2019, MDNA Life Sciences launched a new prostate cancer test in United Kingdom, which is beneficial in providing diagnostic tests of individuals and strengthening its product portfolio by introducing the new Mitomic Prostate Test (MPT) for clinical use.

Prostate Cancer Testing Market Dynamics:
AttributesDetails
Growth Drivers
  • Increase Prevalence of Prostate Cancer
  • Growing Awareness Regarding the Diseases
Influencing Trends
  • increasing demand in Asia Pacific region
  • Rise in government initiatives to enhance research associated with effective diagnosis and treatment
Restraints
  • High Cost Associated With Prostate Cancer Testing
  • Accuracy and Efficiency of Testing Hamper the Market
Gaps & Opportunities
  • Upsurge Demand for Healthcare Expenditure to its Various Health Benefits.
  • Technological Advancements such as MRI and Fusion Biopsy
  • Approval of new diagnostic tests


AMA Research follows a focused and realistic research framework that provides the ability to study the crucial market dynamics in several regions across the world. Moreover, an in-depth assessment is mostly conducted by our analysts on geographical regions to provide clients and businesses the opportunity to dominate in niche markets and expand in emerging markets across the globe. This market research study also showcases the spontaneously changing Players landscape impacting the growth of the market. Furthermore, our market researchers extensively analyze the products and services offered by multiple players competing to increase their market share and presence.

Customization in the Report
AMA Research features not only specific market forecasts but also includes significant value-added commentary on:
- Market Trends
- Technological Trends and Innovations
- Market Maturity Indicators
- Growth Drivers and Constraints in Prostate Cancer Testing Market
- Analysis about New Entrants in Prostate Cancer Testing Market & Entry/Exit Barriers
- To Seize Powerful Market Opportunities
- Identify Key Business Segments, Market Proposition & Gap Analysis
- An Unbiased Perspective towards Market Performance & Indicators

Against this Challenging Backdrop, Prostate Cancer Testing Study Sheds Light on
— The Prostate Cancer Testing Market status quo and key characteristics. To end this, Analysts at AMA organize and took surveys of the Prostate Cancer Testing industry Players. The resultant snapshot serves as a basis for understanding why and how the industry can be expected to change.
— Where Prostate Cancer Testing industry is heading and what are the top priorities. Insights are drawn from financial analysis, the survey, and interviews with key executives and industry experts.
— How every company in this diverse set of Players can best navigate the emerging competition landscape and follow a strategy that helps them position to hold the value they currently claim or capture the new addressable opportunity.

Report Objectives / Segmentation Covered

By Type
  • PSA Tests
  • CTC Tests
  • Immunohistochemistry
  • PCA3 Tests
  • Others
By Application
  • Hospital Associated Labs
  • Independent Diagnostic Laboratories
  • Cancer Research Institutes
  • Others
By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increase Prevalence of Prostate Cancer
      • 3.2.2. Growing Awareness Regarding the Diseases
    • 3.3. Market Challenges
      • 3.3.1. Stringent Government Rules and Regulations
      • 3.3.2. Stiff Competition between Major Players
    • 3.4. Market Trends
      • 3.4.1. Increasing demand in Asia Pacific region
      • 3.4.2. Rise in government initiatives to enhance research associated with effective diagnosis and treatment
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Prostate Cancer Testing, by Type, Application and Region (value and price ) (2016-2021)
    • 5.1. Introduction
    • 5.2. Global Prostate Cancer Testing (Value)
      • 5.2.1. Global Prostate Cancer Testing by: Type (Value)
        • 5.2.1.1. PSA Tests
        • 5.2.1.2. CTC Tests
        • 5.2.1.3. Immunohistochemistry
        • 5.2.1.4. PCA3 Tests
        • 5.2.1.5. Others
      • 5.2.2. Global Prostate Cancer Testing by: Application (Value)
        • 5.2.2.1. Hospital Associated Labs
        • 5.2.2.2. Independent Diagnostic Laboratories
        • 5.2.2.3. Cancer Research Institutes
        • 5.2.2.4. Others
      • 5.2.3. Global Prostate Cancer Testing Region
        • 5.2.3.1. South America
          • 5.2.3.1.1. Brazil
          • 5.2.3.1.2. Argentina
          • 5.2.3.1.3. Rest of South America
        • 5.2.3.2. Asia Pacific
          • 5.2.3.2.1. China
          • 5.2.3.2.2. Japan
          • 5.2.3.2.3. India
          • 5.2.3.2.4. South Korea
          • 5.2.3.2.5. Taiwan
          • 5.2.3.2.6. Australia
          • 5.2.3.2.7. Rest of Asia-Pacific
        • 5.2.3.3. Europe
          • 5.2.3.3.1. Germany
          • 5.2.3.3.2. France
          • 5.2.3.3.3. Italy
          • 5.2.3.3.4. United Kingdom
          • 5.2.3.3.5. Netherlands
          • 5.2.3.3.6. Rest of Europe
        • 5.2.3.4. MEA
          • 5.2.3.4.1. Middle East
          • 5.2.3.4.2. Africa
        • 5.2.3.5. North America
          • 5.2.3.5.1. United States
          • 5.2.3.5.2. Canada
          • 5.2.3.5.3. Mexico
    • 5.3. Global Prostate Cancer Testing (Price)
      • 5.3.1. Global Prostate Cancer Testing by: Type (Price)
  • 6. Prostate Cancer Testing: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2021)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Genomic Health (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. OPKO (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Siemens Healthcare (Germany)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. DiaSorin (Italy)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. BioMeriux (France)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Roche (Switzerland)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. MDx Health (Belgium)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Beckman Coulter (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Myriad Genetics (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Ambry Genetics (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Prostate Cancer Testing Sale, by Type, Application and Region (value and price ) (2022-2027)
    • 7.1. Introduction
    • 7.2. Global Prostate Cancer Testing (Value)
      • 7.2.1. Global Prostate Cancer Testing by: Type (Value)
        • 7.2.1.1. PSA Tests
        • 7.2.1.2. CTC Tests
        • 7.2.1.3. Immunohistochemistry
        • 7.2.1.4. PCA3 Tests
        • 7.2.1.5. Others
      • 7.2.2. Global Prostate Cancer Testing by: Application (Value)
        • 7.2.2.1. Hospital Associated Labs
        • 7.2.2.2. Independent Diagnostic Laboratories
        • 7.2.2.3. Cancer Research Institutes
        • 7.2.2.4. Others
      • 7.2.3. Global Prostate Cancer Testing Region
        • 7.2.3.1. South America
          • 7.2.3.1.1. Brazil
          • 7.2.3.1.2. Argentina
          • 7.2.3.1.3. Rest of South America
        • 7.2.3.2. Asia Pacific
          • 7.2.3.2.1. China
          • 7.2.3.2.2. Japan
          • 7.2.3.2.3. India
          • 7.2.3.2.4. South Korea
          • 7.2.3.2.5. Taiwan
          • 7.2.3.2.6. Australia
          • 7.2.3.2.7. Rest of Asia-Pacific
        • 7.2.3.3. Europe
          • 7.2.3.3.1. Germany
          • 7.2.3.3.2. France
          • 7.2.3.3.3. Italy
          • 7.2.3.3.4. United Kingdom
          • 7.2.3.3.5. Netherlands
          • 7.2.3.3.6. Rest of Europe
        • 7.2.3.4. MEA
          • 7.2.3.4.1. Middle East
          • 7.2.3.4.2. Africa
        • 7.2.3.5. North America
          • 7.2.3.5.1. United States
          • 7.2.3.5.2. Canada
          • 7.2.3.5.3. Mexico
    • 7.3. Global Prostate Cancer Testing (Price)
      • 7.3.1. Global Prostate Cancer Testing by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Prostate Cancer Testing: by Type(USD Million)
  • Table 2. Prostate Cancer Testing PSA Tests , by Region USD Million (2016-2021)
  • Table 3. Prostate Cancer Testing CTC Tests , by Region USD Million (2016-2021)
  • Table 4. Prostate Cancer Testing Immunohistochemistry , by Region USD Million (2016-2021)
  • Table 5. Prostate Cancer Testing PCA3 Tests , by Region USD Million (2016-2021)
  • Table 6. Prostate Cancer Testing Others , by Region USD Million (2016-2021)
  • Table 7. Prostate Cancer Testing: by Application(USD Million)
  • Table 8. Prostate Cancer Testing Hospital Associated Labs , by Region USD Million (2016-2021)
  • Table 9. Prostate Cancer Testing Independent Diagnostic Laboratories , by Region USD Million (2016-2021)
  • Table 10. Prostate Cancer Testing Cancer Research Institutes , by Region USD Million (2016-2021)
  • Table 11. Prostate Cancer Testing Others , by Region USD Million (2016-2021)
  • Table 12. South America Prostate Cancer Testing, by Country USD Million (2016-2021)
  • Table 13. South America Prostate Cancer Testing, by Type USD Million (2016-2021)
  • Table 14. South America Prostate Cancer Testing, by Application USD Million (2016-2021)
  • Table 15. Brazil Prostate Cancer Testing, by Type USD Million (2016-2021)
  • Table 16. Brazil Prostate Cancer Testing, by Application USD Million (2016-2021)
  • Table 17. Argentina Prostate Cancer Testing, by Type USD Million (2016-2021)
  • Table 18. Argentina Prostate Cancer Testing, by Application USD Million (2016-2021)
  • Table 19. Rest of South America Prostate Cancer Testing, by Type USD Million (2016-2021)
  • Table 20. Rest of South America Prostate Cancer Testing, by Application USD Million (2016-2021)
  • Table 21. Asia Pacific Prostate Cancer Testing, by Country USD Million (2016-2021)
  • Table 22. Asia Pacific Prostate Cancer Testing, by Type USD Million (2016-2021)
  • Table 23. Asia Pacific Prostate Cancer Testing, by Application USD Million (2016-2021)
  • Table 24. China Prostate Cancer Testing, by Type USD Million (2016-2021)
  • Table 25. China Prostate Cancer Testing, by Application USD Million (2016-2021)
  • Table 26. Japan Prostate Cancer Testing, by Type USD Million (2016-2021)
  • Table 27. Japan Prostate Cancer Testing, by Application USD Million (2016-2021)
  • Table 28. India Prostate Cancer Testing, by Type USD Million (2016-2021)
  • Table 29. India Prostate Cancer Testing, by Application USD Million (2016-2021)
  • Table 30. South Korea Prostate Cancer Testing, by Type USD Million (2016-2021)
  • Table 31. South Korea Prostate Cancer Testing, by Application USD Million (2016-2021)
  • Table 32. Taiwan Prostate Cancer Testing, by Type USD Million (2016-2021)
  • Table 33. Taiwan Prostate Cancer Testing, by Application USD Million (2016-2021)
  • Table 34. Australia Prostate Cancer Testing, by Type USD Million (2016-2021)
  • Table 35. Australia Prostate Cancer Testing, by Application USD Million (2016-2021)
  • Table 36. Rest of Asia-Pacific Prostate Cancer Testing, by Type USD Million (2016-2021)
  • Table 37. Rest of Asia-Pacific Prostate Cancer Testing, by Application USD Million (2016-2021)
  • Table 38. Europe Prostate Cancer Testing, by Country USD Million (2016-2021)
  • Table 39. Europe Prostate Cancer Testing, by Type USD Million (2016-2021)
  • Table 40. Europe Prostate Cancer Testing, by Application USD Million (2016-2021)
  • Table 41. Germany Prostate Cancer Testing, by Type USD Million (2016-2021)
  • Table 42. Germany Prostate Cancer Testing, by Application USD Million (2016-2021)
  • Table 43. France Prostate Cancer Testing, by Type USD Million (2016-2021)
  • Table 44. France Prostate Cancer Testing, by Application USD Million (2016-2021)
  • Table 45. Italy Prostate Cancer Testing, by Type USD Million (2016-2021)
  • Table 46. Italy Prostate Cancer Testing, by Application USD Million (2016-2021)
  • Table 47. United Kingdom Prostate Cancer Testing, by Type USD Million (2016-2021)
  • Table 48. United Kingdom Prostate Cancer Testing, by Application USD Million (2016-2021)
  • Table 49. Netherlands Prostate Cancer Testing, by Type USD Million (2016-2021)
  • Table 50. Netherlands Prostate Cancer Testing, by Application USD Million (2016-2021)
  • Table 51. Rest of Europe Prostate Cancer Testing, by Type USD Million (2016-2021)
  • Table 52. Rest of Europe Prostate Cancer Testing, by Application USD Million (2016-2021)
  • Table 53. MEA Prostate Cancer Testing, by Country USD Million (2016-2021)
  • Table 54. MEA Prostate Cancer Testing, by Type USD Million (2016-2021)
  • Table 55. MEA Prostate Cancer Testing, by Application USD Million (2016-2021)
  • Table 56. Middle East Prostate Cancer Testing, by Type USD Million (2016-2021)
  • Table 57. Middle East Prostate Cancer Testing, by Application USD Million (2016-2021)
  • Table 58. Africa Prostate Cancer Testing, by Type USD Million (2016-2021)
  • Table 59. Africa Prostate Cancer Testing, by Application USD Million (2016-2021)
  • Table 60. North America Prostate Cancer Testing, by Country USD Million (2016-2021)
  • Table 61. North America Prostate Cancer Testing, by Type USD Million (2016-2021)
  • Table 62. North America Prostate Cancer Testing, by Application USD Million (2016-2021)
  • Table 63. United States Prostate Cancer Testing, by Type USD Million (2016-2021)
  • Table 64. United States Prostate Cancer Testing, by Application USD Million (2016-2021)
  • Table 65. Canada Prostate Cancer Testing, by Type USD Million (2016-2021)
  • Table 66. Canada Prostate Cancer Testing, by Application USD Million (2016-2021)
  • Table 67. Mexico Prostate Cancer Testing, by Type USD Million (2016-2021)
  • Table 68. Mexico Prostate Cancer Testing, by Application USD Million (2016-2021)
  • Table 69. Prostate Cancer Testing: by Type(USD/Units)
  • Table 70. Company Basic Information, Sales Area and Its Competitors
  • Table 71. Company Basic Information, Sales Area and Its Competitors
  • Table 72. Company Basic Information, Sales Area and Its Competitors
  • Table 73. Company Basic Information, Sales Area and Its Competitors
  • Table 74. Company Basic Information, Sales Area and Its Competitors
  • Table 75. Company Basic Information, Sales Area and Its Competitors
  • Table 76. Company Basic Information, Sales Area and Its Competitors
  • Table 77. Company Basic Information, Sales Area and Its Competitors
  • Table 78. Company Basic Information, Sales Area and Its Competitors
  • Table 79. Company Basic Information, Sales Area and Its Competitors
  • Table 80. Prostate Cancer Testing: by Type(USD Million)
  • Table 81. Prostate Cancer Testing PSA Tests , by Region USD Million (2022-2027)
  • Table 82. Prostate Cancer Testing CTC Tests , by Region USD Million (2022-2027)
  • Table 83. Prostate Cancer Testing Immunohistochemistry , by Region USD Million (2022-2027)
  • Table 84. Prostate Cancer Testing PCA3 Tests , by Region USD Million (2022-2027)
  • Table 85. Prostate Cancer Testing Others , by Region USD Million (2022-2027)
  • Table 86. Prostate Cancer Testing: by Application(USD Million)
  • Table 87. Prostate Cancer Testing Hospital Associated Labs , by Region USD Million (2022-2027)
  • Table 88. Prostate Cancer Testing Independent Diagnostic Laboratories , by Region USD Million (2022-2027)
  • Table 89. Prostate Cancer Testing Cancer Research Institutes , by Region USD Million (2022-2027)
  • Table 90. Prostate Cancer Testing Others , by Region USD Million (2022-2027)
  • Table 91. South America Prostate Cancer Testing, by Country USD Million (2022-2027)
  • Table 92. South America Prostate Cancer Testing, by Type USD Million (2022-2027)
  • Table 93. South America Prostate Cancer Testing, by Application USD Million (2022-2027)
  • Table 94. Brazil Prostate Cancer Testing, by Type USD Million (2022-2027)
  • Table 95. Brazil Prostate Cancer Testing, by Application USD Million (2022-2027)
  • Table 96. Argentina Prostate Cancer Testing, by Type USD Million (2022-2027)
  • Table 97. Argentina Prostate Cancer Testing, by Application USD Million (2022-2027)
  • Table 98. Rest of South America Prostate Cancer Testing, by Type USD Million (2022-2027)
  • Table 99. Rest of South America Prostate Cancer Testing, by Application USD Million (2022-2027)
  • Table 100. Asia Pacific Prostate Cancer Testing, by Country USD Million (2022-2027)
  • Table 101. Asia Pacific Prostate Cancer Testing, by Type USD Million (2022-2027)
  • Table 102. Asia Pacific Prostate Cancer Testing, by Application USD Million (2022-2027)
  • Table 103. China Prostate Cancer Testing, by Type USD Million (2022-2027)
  • Table 104. China Prostate Cancer Testing, by Application USD Million (2022-2027)
  • Table 105. Japan Prostate Cancer Testing, by Type USD Million (2022-2027)
  • Table 106. Japan Prostate Cancer Testing, by Application USD Million (2022-2027)
  • Table 107. India Prostate Cancer Testing, by Type USD Million (2022-2027)
  • Table 108. India Prostate Cancer Testing, by Application USD Million (2022-2027)
  • Table 109. South Korea Prostate Cancer Testing, by Type USD Million (2022-2027)
  • Table 110. South Korea Prostate Cancer Testing, by Application USD Million (2022-2027)
  • Table 111. Taiwan Prostate Cancer Testing, by Type USD Million (2022-2027)
  • Table 112. Taiwan Prostate Cancer Testing, by Application USD Million (2022-2027)
  • Table 113. Australia Prostate Cancer Testing, by Type USD Million (2022-2027)
  • Table 114. Australia Prostate Cancer Testing, by Application USD Million (2022-2027)
  • Table 115. Rest of Asia-Pacific Prostate Cancer Testing, by Type USD Million (2022-2027)
  • Table 116. Rest of Asia-Pacific Prostate Cancer Testing, by Application USD Million (2022-2027)
  • Table 117. Europe Prostate Cancer Testing, by Country USD Million (2022-2027)
  • Table 118. Europe Prostate Cancer Testing, by Type USD Million (2022-2027)
  • Table 119. Europe Prostate Cancer Testing, by Application USD Million (2022-2027)
  • Table 120. Germany Prostate Cancer Testing, by Type USD Million (2022-2027)
  • Table 121. Germany Prostate Cancer Testing, by Application USD Million (2022-2027)
  • Table 122. France Prostate Cancer Testing, by Type USD Million (2022-2027)
  • Table 123. France Prostate Cancer Testing, by Application USD Million (2022-2027)
  • Table 124. Italy Prostate Cancer Testing, by Type USD Million (2022-2027)
  • Table 125. Italy Prostate Cancer Testing, by Application USD Million (2022-2027)
  • Table 126. United Kingdom Prostate Cancer Testing, by Type USD Million (2022-2027)
  • Table 127. United Kingdom Prostate Cancer Testing, by Application USD Million (2022-2027)
  • Table 128. Netherlands Prostate Cancer Testing, by Type USD Million (2022-2027)
  • Table 129. Netherlands Prostate Cancer Testing, by Application USD Million (2022-2027)
  • Table 130. Rest of Europe Prostate Cancer Testing, by Type USD Million (2022-2027)
  • Table 131. Rest of Europe Prostate Cancer Testing, by Application USD Million (2022-2027)
  • Table 132. MEA Prostate Cancer Testing, by Country USD Million (2022-2027)
  • Table 133. MEA Prostate Cancer Testing, by Type USD Million (2022-2027)
  • Table 134. MEA Prostate Cancer Testing, by Application USD Million (2022-2027)
  • Table 135. Middle East Prostate Cancer Testing, by Type USD Million (2022-2027)
  • Table 136. Middle East Prostate Cancer Testing, by Application USD Million (2022-2027)
  • Table 137. Africa Prostate Cancer Testing, by Type USD Million (2022-2027)
  • Table 138. Africa Prostate Cancer Testing, by Application USD Million (2022-2027)
  • Table 139. North America Prostate Cancer Testing, by Country USD Million (2022-2027)
  • Table 140. North America Prostate Cancer Testing, by Type USD Million (2022-2027)
  • Table 141. North America Prostate Cancer Testing, by Application USD Million (2022-2027)
  • Table 142. United States Prostate Cancer Testing, by Type USD Million (2022-2027)
  • Table 143. United States Prostate Cancer Testing, by Application USD Million (2022-2027)
  • Table 144. Canada Prostate Cancer Testing, by Type USD Million (2022-2027)
  • Table 145. Canada Prostate Cancer Testing, by Application USD Million (2022-2027)
  • Table 146. Mexico Prostate Cancer Testing, by Type USD Million (2022-2027)
  • Table 147. Mexico Prostate Cancer Testing, by Application USD Million (2022-2027)
  • Table 148. Prostate Cancer Testing: by Type(USD/Units)
  • Table 149. Research Programs/Design for This Report
  • Table 150. Key Data Information from Secondary Sources
  • Table 151. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Prostate Cancer Testing: by Type USD Million (2016-2021)
  • Figure 5. Global Prostate Cancer Testing: by Application USD Million (2016-2021)
  • Figure 6. South America Prostate Cancer Testing Share (%), by Country
  • Figure 7. Asia Pacific Prostate Cancer Testing Share (%), by Country
  • Figure 8. Europe Prostate Cancer Testing Share (%), by Country
  • Figure 9. MEA Prostate Cancer Testing Share (%), by Country
  • Figure 10. North America Prostate Cancer Testing Share (%), by Country
  • Figure 11. Global Prostate Cancer Testing: by Type USD/Units (2016-2021)
  • Figure 12. Global Prostate Cancer Testing share by Players 2021 (%)
  • Figure 13. Global Prostate Cancer Testing share by Players (Top 3) 2021(%)
  • Figure 14. Global Prostate Cancer Testing share by Players (Top 5) 2021(%)
  • Figure 15. BCG Matrix for key Companies
  • Figure 16. Genomic Health (United States) Revenue, Net Income and Gross profit
  • Figure 17. Genomic Health (United States) Revenue: by Geography 2021
  • Figure 18. OPKO (United States) Revenue, Net Income and Gross profit
  • Figure 19. OPKO (United States) Revenue: by Geography 2021
  • Figure 20. Siemens Healthcare (Germany) Revenue, Net Income and Gross profit
  • Figure 21. Siemens Healthcare (Germany) Revenue: by Geography 2021
  • Figure 22. DiaSorin (Italy) Revenue, Net Income and Gross profit
  • Figure 23. DiaSorin (Italy) Revenue: by Geography 2021
  • Figure 24. BioMeriux (France) Revenue, Net Income and Gross profit
  • Figure 25. BioMeriux (France) Revenue: by Geography 2021
  • Figure 26. Roche (Switzerland) Revenue, Net Income and Gross profit
  • Figure 27. Roche (Switzerland) Revenue: by Geography 2021
  • Figure 28. MDx Health (Belgium) Revenue, Net Income and Gross profit
  • Figure 29. MDx Health (Belgium) Revenue: by Geography 2021
  • Figure 30. Beckman Coulter (United States) Revenue, Net Income and Gross profit
  • Figure 31. Beckman Coulter (United States) Revenue: by Geography 2021
  • Figure 32. Myriad Genetics (United States) Revenue, Net Income and Gross profit
  • Figure 33. Myriad Genetics (United States) Revenue: by Geography 2021
  • Figure 34. Ambry Genetics (United States) Revenue, Net Income and Gross profit
  • Figure 35. Ambry Genetics (United States) Revenue: by Geography 2021
  • Figure 36. Global Prostate Cancer Testing: by Type USD Million (2022-2027)
  • Figure 37. Global Prostate Cancer Testing: by Application USD Million (2022-2027)
  • Figure 38. South America Prostate Cancer Testing Share (%), by Country
  • Figure 39. Asia Pacific Prostate Cancer Testing Share (%), by Country
  • Figure 40. Europe Prostate Cancer Testing Share (%), by Country
  • Figure 41. MEA Prostate Cancer Testing Share (%), by Country
  • Figure 42. North America Prostate Cancer Testing Share (%), by Country
  • Figure 43. Global Prostate Cancer Testing: by Type USD/Units (2022-2027)
List of companies from research coverage that are profiled in the study
  • Genomic Health (United States)
  • OPKO (United States)
  • Siemens Healthcare (Germany)
  • DiaSorin (Italy)
  • BioMeriux (France)
  • Roche (Switzerland)
  • MDx Health (Belgium)
  • Beckman Coulter (United States)
  • Myriad Genetics (United States)
  • Ambry Genetics (United States)
Select User Access Type

Key Highlights of Report


Jul 2022 197 Pages 87 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Prostate Cancer Testing Quantitative research analysis
Global Prostate Cancer Testing Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

Top performing companies in the Global Prostate Cancer Testing market are Genomic Health (United States), OPKO (United States), Siemens Healthcare (Germany), DiaSorin (Italy), BioMeriux (France), Roche (Switzerland), MDx Health (Belgium), Beckman Coulter (United States), Myriad Genetics (United States) and Ambry Genetics (United States), to name a few.
North America is dominating the Prostate Cancer Testing Market.
"Stringent Government Rules and Regulations " is seen as one of major challenge by many Industry Players of Prostate Cancer Testing Market
The Prostate Cancer Testing market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get complete companies available in our research coverage.
The Prostate Cancer Testing market is expected to see a steady growth rate during projected year 2021 to 2027.

Know More About Global Prostate Cancer Testing Report?

Have a Query? Click Here

Other Related Reports

Surgical Waste Management Comprehensive Study by Type (Bio-hazardous Waste Disposal Management, Non-Hazardous Pharmaceutical Waste Management, Pathological Waste Management, Others), Application (Hos...
$ 3750
Dengue Vaccines Comprehensive Study by Application (Prevention of dengue, Enhanced the immunity), End Users (Government organizations, Medical clinics, Non-profit Organization, Diagnostic centers), V...
$ 3650
Sample Preparation Comprehensive Study by Type (Sample preparation instruments, Consumables, Sample preparation kits, Accessories), Application (Pharmaceutical industries, Biotechnology, Diagnostic l...
$ 3750
Gout Therapeutics Comprehensive Study by Type (NSAIDs, Corticosteroids, Colchicine, Urate-Lowering Agents), Application (Hospitals, Clinics), Diseases Type (Acute Gout, Chronic Gout) Players and Regi...
$ 3500
Air Ambulance Services Comprehensive Study by Mission Profile (Inter Facility Transport, Scene Response, Others), Service Model (Community Based, Hospital Based, Hybrid), Aircraft Type (Fixed Wing ...
$ 3350
Health Information Systems Comprehensive Study by Application (Electronic Health Record, Real-Time Healthcare, Population Health Management, Transfer of Information), End Users (Hospitals, Pharmacy, ...
$ 3650